Accessibility Menu
Annovis Bio Stock Quote

Annovis Bio (NYSE: ANVS)

$2.02
(-6.9%)
-0.15
Price as of October 22, 2025, 3:21 p.m. ET

KEY DATA POINTS

Current Price
$2.03
Daily Change
(-6.9%) $0.15
Day's Range
$1.97 - $2.15
Previous Close
$2.03
Open
$2.1
Beta
1.47
Volume
477,667
Average Volume
581,985
Market Cap
47.3M
Market Cap / Employee
$2.03M
52wk Range
$1.11 - $10.54
Revenue
-
Gross Margin
-
Dividend Yield
N/A
EPS
-$2.09
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Annovis Bio Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
ANVS-78.92%-59.96%-16.73%-79%
S&P+14.5%+93.32%+14.09%+105%

Annovis Bio Company Info

Annovis Bio, Inc. is a clinical stage drug platform company, which engages in the development of drugs which aims to treat neurodegenerative diseases such as Alzheimer’s (AD) and Parkinson’s (PD). Its lead product candidate, Buntanetap, is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Its product pipeline also includes ANVS405 and ANVS301, which focus on the treatment of traumatic brain injury, stroke, and advanced AD. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Berwyn, PA.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$0.00M0.0%
Gross Profit$0.00M0.0%
Market Cap$42.29M-34.3%
Market Cap / Employee$5.29M0.0%
Employees833.3%
Net Income-$6.22M-23.9%
EBITDA-$6.27M19.2%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$17.13M328.5%
Inventory00.0%

Liabilities

Q2 2025YOY Change
Long Term Debt$0.00M0.0%
Short Term Debt$0.00M0.0%

Ratios

Q2 2025YOY Change
Return On Assets-228.37%80.4%
Return On Invested Capital53.31%-72.7%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$5.11M-51.3%
Operating Free Cash Flow-$5.11M-51.3%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book-53.969.462.281.76-109.30%
Price to Tangible Book Value-53.969.462.281.76-109.30%
Enterprise Value to EBITDA-20.96-8.74-0.62-4.01-49.07%
Return on Equity-596.7%-3159.1%-280.8%-365.0%-19.42%
Total Debt$0.00M$0.00M$0.00M$0.00M-

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.